Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study to Evaluate the Efficacy, Safety, and Tolerability of NDI-034858 in Subjects With Active Psoriatic Arthritis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05153148
Recruitment Status : Recruiting
First Posted : December 10, 2021
Last Update Posted : May 5, 2022
Sponsor:
Information provided by (Responsible Party):
Nimbus Therapeutics ( Nimbus Lakshmi, Inc. )

Brief Summary:
This study is designed to evaluate the efficacy, safety, and tolerability of NDI-034858 in subjects with active Psoriatic Arthritis (PsA).

Condition or disease Intervention/treatment Phase
Psoriatic Arthritis Drug: NDI-034858 Other: Placebo Phase 2

Detailed Description:

This is a Phase 2b, Randomized, Multi-center, Double-Blind, Placebo-Controlled, Multiple Dose Study .

Randomization to one of the treatments with NDI-034858 Dose 1, 2, 3 or placebo once daily (QD) will be based on a 1:1:1:1 scheme.

The maximum study duration per subject is approximately 20 weeks, including up to 30 days for the screening period, a 12-week treatment period, and a 4-week safety follow-up period.

Efficacy will be assessed using the ACR20 composite measure (including tender and swollen joint count, patient assessment of PsA pain visual analog scale (VAS), patient global PsA assessment VAS, physician global PsA assessment, HAQ-DI, and hsCRP) as well as the additional components. Efficacy for psoriasis among subjects who have ≥ 3% BSA) involvement on Day 1, will be measured using PASI, PGAs, and BSA.

Safety will be assessed by collecting AEs, recording vital signs, performing physical examinations, and evaluating clinical laboratory and ECGs results.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 260 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Masking Description: Treatment and randomization information will be kept confidential and will not be released to the investigator, the study staff, the contract research organization (CRO), or the sponsor's study team until after the conclusion of the study.
Primary Purpose: Treatment
Official Title: A Phase 2b, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, Multiple Dose Study to Evaluate the Efficacy, Safety, and Tolerability of NDI-034858 in Subjects With Active Psoriatic Arthritis
Actual Study Start Date : January 6, 2022
Estimated Primary Completion Date : May 2023
Estimated Study Completion Date : May 2023

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: NDI-034858 study drug - Dose 1
NDI-034858 study drug will be orally administered QD for 12 weeks
Drug: NDI-034858
Randomized participants will receive NDI-034858 capsule orally

Experimental: NDI-034858 study drug - Dose 2
NDI-034858 study drug will be orally administered QD for 12 weeks
Drug: NDI-034858
Randomized participants will receive NDI-034858 capsule orally

Experimental: NDI-034858 study drug - Dose 3
NDI-034858 study drug will be orally administered QD for 12 weeks
Drug: NDI-034858
Randomized participants will receive NDI-034858 capsule orally

Placebo Comparator: Placebo
Placebo will be orally administered QD for 12 weeks
Other: Placebo
Randomized participants will receive placebo orally




Primary Outcome Measures :
  1. Proportion of subjects achieving at least an American College of Rheumatology (ACR) 20 response [ Time Frame: Day 1 to Week 16 ]
    The ACR20 is a composite measure defined as both improvement of 20% in the number of tender (68) and number of swollen (66) joints, and a 20% improvement in three of the following five criteria: patient global assessment of psoriatic arthritis, physician global assessment of psoriatic arthritis, patient pain scale, disability history questionnaire (ie, HAQ-DI) and an acute phase reactant (ie, erythrocyte sedimentation rate [ESR] or hsCRP). For this primary endpoint, hsCRP will be used.


Secondary Outcome Measures :
  1. Proportion of subjects achieving at least an ACR-50 or ACR-70 response [ Time Frame: Day 1 to Week 16 ]
    The ACR-50 and ACR-70 are a composite measure defined as both improvement of 50% or 70%, respectively, in the number of tender (68) and number of swollen (66) joints, and a 50% or 70%, respectively, improvement in three of the following five criteria: patient global assessment of psoriatic arthritis, physician global assessment of psoriatic arthritis, patient pain scale, disability history questionnaire (ie, HAQ-DI) and an acute phase reactant (ie, ESR or CRP).

  2. Change from baseline in tender joint count (TJC) [ Time Frame: From screening until Week 12 ]
    The TJC 68 are a total score of points assigned for presence of tenderness in the following: Temporomandibular, sternoclavicular, acromioclavicular, shoulder, elbow, wrist, hip, knee, ankle, tarsus, typically assigned 2 points each; Metacarpophalangeal, finger proximal interphalangeal, metatarsophalangeal, toe proximal interphalangeal, typically assigned 10 points each; Distal interphalangeal, typically assigned 8 points.

  3. Change from baseline in swollen joint count (SJC) [ Time Frame: From screening until Week 12 ]
    The SJC 66 (SJC minus hip joints, which cannot be assessed for swelling) are a total score of points assigned for presence of swelling in the following: Temporomandibular, sternoclavicular, acromioclavicular, shoulder, elbow, wrist, knee, ankle, tarsus, typically assigned 2 points each; Metacarpophalangeal, finger proximal interphalangeal, metatarsophalangeal, toe proximal interphalangeal, typically assigned 10 points each; Distal interphalangeal, typically assigned 8 points.

  4. Change from baseline in Patient Global Assessment of Psoriatic Arthritis [ Time Frame: Day 1 to Week 16 ]
    Subjects will rate their assessment of their PsA using a VAS where 0 is 'very good, no symptoms' and 100 is 'very poor, severe symptoms'.

  5. Change from baseline in Patient Global Assessment of Psoriatic Arthritis pain [ Time Frame: Day 1 to Week 16 ]
    Subjects will rate their assessment of their PsA using a VAS where 0 is 'no pain' and 100 is 'most severe pain'.

  6. Change from baseline in Physician Global Assessment of Psoriatic Arthritis [ Time Frame: Day 1 to Week 16 ]
    The patients' overall disease status will be assessed, taking into account signs, symptoms, and function, of all components of joint and skin which is affected at the time of the visit and will rate this overall status using a VAS scale where 0 is 'very good, asymptomatic, and no limitation of normal activities' and 100 is 'very poor, very severe symptoms which are intolerable, and inability to carry out all normal activities'.

  7. Change from baseline in Health Activities Questionnaire - Disability Index (HAQ-DI) score [ Time Frame: Day 1 to Week 16 ]
    The HAQ-DI is comprised of eight domains: dressing, arising, eating, walking, hygiene, reach, grip, and activities. There are two or three questions per section. Scoring within each section is from 0 (without any difficulty) to 3 (unable to do). For each section the score given to that section is the worst score within the section (ie, if one question is scored 1 and another 2, then the score for the section is 2).

  8. Change from baseline in dactylitis count [ Time Frame: Day 1 to Week 16 ]
    The dactylitis count consists of totaling the number of single digits in the hands and feet with tenderness.

  9. Change from baseline in Leed's Enthesitis Index (LEI) [ Time Frame: Day 1 to Week 16 ]
    The LEI is comprised of review of six bilateral sites: Achilles tendon insertions, medial femoral condyles, and lateral epicondyles of the humerus. Tenderness at each site is quantified on a dichotomous basis: 0 means nontender and 1 means tender.

  10. Change from baseline in Physician Global Assessment of Psoriasis [ Time Frame: Day 1 to Week 16 ]
    The PGA is measured using a 0 to 4 scale with a 0 score meaning cleared and a 4 score meaning severe and a ≥ 2 grade improvement from baseline.

  11. Change from baseline in Disease Activity Score 28 with CRP(DAS28-CRP) [ Time Frame: Day 1 to Week 16 ]
    The DAS28-CRP describes the severity of PsA using clinical and laboratory data, specifically hsCRP. The DAS scores indicate how active a subject's psoriatic arthritis is currently and can be trended over time.

  12. Incidence of AEs and TAEs [ Time Frame: Day 1 to Week 16 ]
    The safety and tolerability of NDI-034858 will be assessed.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subject has PsA on the basis of the Classification Criteria for Psoriatic Arthritis with peripheral symptoms at the screening visit.
  • Subject has a history of PsA symptoms for ≥ 6 months prior to the screening visit.
  • Subject has ≥ 3 tender joints and ≥ 3 swollen joints at screening and Day 1 visits.
  • Subject has at least one lesion of plaque psoriasis ≥ 2 cm in diameter, nail changes characteristic of psoriasis, or a documented history of plaque psoriasis.
  • Subject has active PsA despite previous standard doses of non-steroidal anti-inflammatory drug (NSAIDs) administered for ≥ 4 weeks, or traditional disease-modifying anti-rheumatic drug (DMARDs) (including methotrexate and sulfasalazine) administered for ≥ 3 months, or tumor necrosis factor inhibitor (TNFi) agents administered for ≥ 3 months, or subjects are intolerant to NSAIDs or DMARDs or TNFi agents.
  • If subject is on concurrent PsA treatments, they must be on stable doses.
  • All female subjects should followed the protocol defined contraceptive method.

Exclusion Criteria:

  • Subject has other disease(s) that might confound the evaluations of benefit of NDI-034858 therapy, including but not limited to rheumatoid arthritis (RA), axial spondyloarthritis (this does not include a primary diagnosis of PsA with spondylitis), systemic lupus erythematosus, Lyme disease, or fibromyalgia.
  • Subject has a history of lack of response to any therapeutic agent targeting IL-12, IL17, and/or IL23 at approved doses after at least 12 weeks of therapy, and/or received one of these therapies within 6 months prior to baseline (Day 1).
  • Subject has a history of lack of response to > 1 therapeutic agent targeting tumor necrosis factor.
  • Subject has received infliximab, golimumab, adalimumab, or certolizumab pegol, or any biosimilar of these agents, within 8 weeks prior to baseline (Day 1).
  • Subject has received etanercept, or any biosimilar of etanercept, within 4 weeks prior to baseline (Day 1).
  • Subject has received rituximab or any immune-cell-depleting therapy within 6 months prior to baseline (Day 1).
  • Subject has received any marketed or investigational biological agent, other than those specified in other inclusion/exclusion criteria, within 12 weeks or 5 half-lives prior to baseline (Day 1).
  • Subject is currently receiving a non-biological investigational product or device or has received one within 4 weeks prior to baseline (Day 1).
  • Subject has received apremilast or other non-biologic systemic treatment for PsA within 4 weeks prior to baseline (Day 1), other than methotrexate (MTX), sulfasalazine, corticosteroids, NSAIDs, or paracetamol/acetaminophen, which are allowed at stable doses as described in Inclusion Criterion 7. For subjects not receiving MTX and sulfasalazine at screening, MTX and sulfasalazine are excluded within 4 weeks prior to baseline (Day 1). Subject has received leflunomide within 8 weeks of baseline (Day 1) if no elimination procedure was followed or adhere to an elimination procedure. For subjects not receiving MTX and sulfasalazine at Screening, MTX and sulfasalazine are excluded within 4 weeks prior to baseline (Day 1).
  • Subject has received intraarticular injection (including corticosteroids), intramuscular steroids, intralesional steroids, or intravenous steroids within 4 weeks prior to baseline (Day 1). For subjects not receiving MTX and sulfasalazine at screening, MTX and sulfasalazine are excluded within 4 weeks prior to baseline (Day 1). For subjects not receiving MTX and sulfasalazine at screening, MTX and sulfasalazine are excluded within 4 weeks prior to baseline (Day 1).
  • Subject has received high potency opioid analgesics (eg, methadone, hydromorphone, or morphine) within 2 weeks prior to baseline (Day 1).
  • Subject has used any topical medication that could affect PsA or psoriasis (including corticosteroids, retinoids, vitamin D analogues (such as calcipotriol), JAK inhibitors, or tar) within 2 weeks prior to baseline (Day 1).
  • Subject has used any systemic treatment that could affect PsA or psoriasis (including oral retinoids, immunosuppressive/immunomodulating medication, cyclosporine, oral JAK inhibitors, or apremilast) within 4 weeks prior to baseline (Day 1).
  • Subject has received any ultraviolet (UV)-B phototherapy (including tanning beds) or excimer laser within 4 weeks prior to baseline (Day 1).
  • Subject has had psoralen and UV A (PUVA) treatment within 4 weeks prior to baseline (Day 1).
  • Subject has received Chinese traditional medicine within 4 weeks prior to baseline (Day 1)
  • Subject has received any live-attenuated vaccine, including for COVID-19, within 4 weeks prior to baseline (Day 1) or plans to receive a live-attenuated vaccine during the study and up to 4 weeks or 5 half-lives of the study drug, whichever is longer, after the last study drug administration.
  • Subject is currently being treated with strong or moderate cytochrome P450 3A (CYP3A4) inhibitors, such as itraconazole or has received moderate or strong CYP3A4 inhibitors within 4 weeks prior to baseline (Day 1).
  • Subject has consumed grapefruit or grapefruit juice within 1 week prior to baseline (Day 1).
  • Subject has used tanning booths within 4 weeks prior to baseline (Day 1), has had excessive sun exposure, or is not willing to minimize natural and artificial sunlight exposure during the study.
  • Subject is a female who is breastfeeding, pregnant, or who is planning to become pregnant during the study.
  • Subject has evidence of erythrodermic, pustular, predominantly guttate psoriasis, or drug-induced psoriasis.
  • Subject has a history of skin disease or presence of skin condition that, in the opinion of the investigator, would interfere with the study assessments.
  • Subject has any clinically significant medical condition, evidence of an unstable clinical condition, psychiatric condition, or vital signs/physical/laboratory/ECG abnormality that would, in the opinion of the investigator, put the subject at undue risk or interfere with interpretation of study results.
  • Subject had a major surgery within 8 weeks prior to baseline (Day 1 or has a major surgery planned during the study.
  • Subject has a history of Class III or IV congestive heart failure as defined by New York Heart Association Criteria.
  • Subject has an estimated creatinine clearance of < 40 mL/min based on the Cockcroft-Gault equation or a history of renal failure.
  • Subject was hospitalized in the 3 months prior to screening for asthma, has ever required intubation for treatment of asthma, currently require oral corticosteroids for the treatment of asthma, or has required more than one short-term (≤ 2 weeks) course of oral corticosteroids for asthma within 6 months prior to baseline (Day 1).
  • Subject has a history of cancer or lymphoproliferative disease within 5 years prior to baseline (Day 1). Subjects with successfully treated nonmetastatic cutaneous squamous cell or basal cell carcinoma and/or localized carcinoma in situ of the cervix are not to be excluded.
  • Subject has a history of fever, inflammation, or systemic signs of illness suggestive of systemic or invasive infection within 4 weeks prior to baseline (Day 1).
  • Subject has an active bacterial, viral, fungal, mycobacterial infection, or other infection (including TB or atypical mycobacterial disease), or any major episode of infection that required hospitalization or treatment with intravenous antibiotics within 12 weeks prior to baseline (Day 1), or oral antibiotics within 4 weeks prior to baseline (Day 1).
  • Subject has a history of chronic or recurrent infectious disease, including but not limited to chronic renal infection, chronic chest infection, recurrent urinary tract infection, fungal infection (with the exception of superficial fungal infection of the nailbed), or infected skin wounds or ulcers.
  • Subject has a history of an infected joint prosthesis or has received antibiotics for a suspected infection of a joint prosthesis, if that prosthesis has not been removed or replaced.
  • Subject has active herpes infection, including herpes simplex 1 and 2 and herpes zoster within 8 weeks prior to Day 1.
  • Subject has a history of known or suspected congenital or acquired immunodeficiency state or condition that would compromise the subject's immune status (eg, history of splenectomy, primary immunodeficiency).
  • Subject has positive results for hepatitis B surface antigens (HBsAg), antibodies to hepatitis B core antigens (anti-HBc), hepatitis C virus (HCV), or human immunodeficiency virus (HIV). Samples testing positive for HCV antibodies will require polymerase chain reaction (PCR) qualitative testing for HCV RNA.
  • Subject has clinical or laboratory evidence of active or latent TB infection at screening as assessed by QuantiFERON-TB Gold (or a purified protein derivative [PPD] skin test or equivalent, or both if required per local guidelines) and chest X-ray. The PPD skin test should be utilized only when a QuantiFERON-TB Gold Test is not possible for any reason (unless local guidelines require both tests). Chest X-ray may be taken at screening or completed within 3 months prior to the screening visit, with documentation showing no evidence of infection or malignancy as read by a qualified physician.
  • Subject has a known or suspected allergy to NDI-034858 or any component of the investigational product, or any other significant drug allergy (such as anaphylaxis or hepatotoxicity).
  • Subject has a known history of clinically significant drug or alcohol abuse in the last year prior to baseline (Day 1).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05153148


Contacts
Layout table for location contacts
Contact: Study Coordinator 857-999-2009 clinical@nimbustx.com

Locations
Layout table for location information
United States, California
Nimbus site #XYZ Recruiting
Palm Desert, California, United States, 92260-9368
Contact: Study Coordinator         
Nimbus site #XYZ Not yet recruiting
Upland, California, United States, 91786
Contact: Study Coordinator         
United States, Florida
Nimbus site #XYZ Recruiting
Hollywood, Florida, United States, 33024
Contact: Study Coordinator         
Nimbus site #XYZ Not yet recruiting
New Port Richey, Florida, United States, 34652
Contact: Study Coordinator         
Nimbus site #XYZ Not yet recruiting
Ormond Beach, Florida, United States, 32174
Contact: Study Coordinator         
Nimbus site #XYZ Not yet recruiting
Plantation, Florida, United States, 33324
Contact: Study Coordinator         
Nimbus site #XYZ Recruiting
Saint Petersburg, Florida, United States, 33705
Contact: Study Coordinator         
Nimbus site #XYZ Recruiting
Tampa, Florida, United States, 33613
Contact: Study Coordinator         
Nimbus site #XYZ Recruiting
Tampa, Florida, United States, 33614
Contact: Study Coordinator         
Nimbus site #XYZ Recruiting
Winter Park, Florida, United States, 32789
Contact: Study Coordinator         
Nimbus site #XYZ Recruiting
Zephyrhills, Florida, United States, 33542
Contact: Study Coordinator         
United States, Georgia
Nimbus site #XYZ Not yet recruiting
Atlanta, Georgia, United States, 30342
Contact: Study Coordinator         
United States, Massachusetts
Nimbus site #XYZ Recruiting
Worcester, Massachusetts, United States, 01605
Contact: Study Coordinator         
United States, New Mexico
Nimbus site #XYZ Not yet recruiting
Albuquerque, New Mexico, United States, 87102
Contact: Study Coordinator         
United States, North Carolina
Nimbus site #XYZ Recruiting
Charlotte, North Carolina, United States, 28210
Contact: Study Coordinator         
United States, Pennsylvania
Nimbus site #XYZ Recruiting
Duncansville, Pennsylvania, United States, 16635
Contact: Study Coordinator         
Nimbus site #XYZ Not yet recruiting
Wyomissing, Pennsylvania, United States, 19610
Contact: Study Coordinator         
United States, Tennessee
Nimbus site #XYZ Recruiting
Jackson, Tennessee, United States, 38305
Contact: Study Coordinator         
United States, Texas
Nimbus site #XYZ Recruiting
Baytown, Texas, United States, 77521
Contact: Study Coordinator         
Nimbus site #XYZ Recruiting
Corpus Christi, Texas, United States, 78404
Contact: Study Coordinator         
Nimbus site #XYZ Recruiting
Houston, Texas, United States, 77089
Contact: Study Coordinator         
Nimbus site #XYZ Recruiting
Mesquite, Texas, United States, 75150
Contact: Study Coordinator         
United States, West Virginia
Nimbus site #XYZ Recruiting
Beckley, West Virginia, United States, 25801
Contact: Study Coordinator         
Sponsors and Collaborators
Nimbus Lakshmi, Inc.
Investigators
Layout table for investigator information
Study Director: Esha Gangolli, PhD Nimbus Lakshmi, Inc.
Layout table for additonal information
Responsible Party: Nimbus Lakshmi, Inc.
ClinicalTrials.gov Identifier: NCT05153148    
Other Study ID Numbers: 4858-202
First Posted: December 10, 2021    Key Record Dates
Last Update Posted: May 5, 2022
Last Verified: April 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Nimbus Therapeutics ( Nimbus Lakshmi, Inc. ):
Placebo-Controlled
Double-blind
Multiple-dose study
Additional relevant MeSH terms:
Layout table for MeSH terms
Arthritis
Arthritis, Psoriatic
Joint Diseases
Musculoskeletal Diseases
Spondylarthropathies
Spondylarthritis
Spondylitis
Spinal Diseases
Bone Diseases
Psoriasis
Skin Diseases, Papulosquamous
Skin Diseases